These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up. Davidkin I, Valle M, Julkunen I. Vaccine; 1995 Nov; 13(16):1617-22. PubMed ID: 8578851 [Abstract] [Full Text] [Related]
3. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella. Tischer A, Gerike E. Vaccine; 2000 Jan 31; 18(14):1382-92. PubMed ID: 10618536 [Abstract] [Full Text] [Related]
4. Seroconversion of a trivalent measles, mumps, and rubella vaccine in children aged 9 and 15 months. Forleo-Neto E, Carvalho ES, Fuentes IC, Precivale MS, Forleo LH, Farhat CK. Vaccine; 1997 Dec 31; 15(17-18):1898-901. PubMed ID: 9413099 [Abstract] [Full Text] [Related]
5. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients. King SM, Saunders EF, Petric M, Gold R. Bone Marrow Transplant; 1996 Apr 31; 17(4):633-6. PubMed ID: 8722367 [Abstract] [Full Text] [Related]
6. Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination. A 15-year follow-up in Finland. Davidkin I, Peltola H, Leinikki P, Valle M. Vaccine; 2000 Jul 15; 18(27):3106-12. PubMed ID: 10856790 [Abstract] [Full Text] [Related]
12. MMR vaccination, measles epidemiology and sero-surveillance in the Republic of Ireland. Johnson H, Hillary IB, McQuoid G, Gilmer BA. Vaccine; 1995 Apr 25; 13(6):533-7. PubMed ID: 7483773 [Abstract] [Full Text] [Related]
13. Previous exposure to measles, mumps, and rubella--but not vaccination during adolescence--correlates to the prevalence of pancreatic and thyroid autoantibodies. Lindberg B, Ahlfors K, Carlsson A, Ericsson UB, Landin-Olsson M, Lernmark A, Ludvigsson J, Sundkvist G, Ivarsson SA. Pediatrics; 1999 Jul 25; 104(1):e12. PubMed ID: 10390298 [Abstract] [Full Text] [Related]
15. Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children. Usonis V, Bakasenas V, Chitour K, Clemens R. Infection; 1998 Jul 25; 26(4):222-6. PubMed ID: 9717679 [Abstract] [Full Text] [Related]
19. Decline in rates of seropositivity for measles, mumps, and rubella antibodies among previously immunized children treated for acute leukemia. Feldman S, Andrew M, Norris M, McIntyre B, Iyer R. Clin Infect Dis; 1998 Aug 25; 27(2):388-90. PubMed ID: 9709893 [Abstract] [Full Text] [Related]
20. Immunity to rubella before and after vaccination against measles, mumps and rubella (MMR) at 12 years of age of the first generation offered MMR vaccination in Sweden at 18 months. Böttiger M. Vaccine; 1995 Dec 25; 13(18):1759-62. PubMed ID: 8701590 [Abstract] [Full Text] [Related] Page: [Next] [New Search]